| Sleckman, Bethany G |
NCT01041703: Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
|
|
| Recruiting | 3 | 747 | US, RoW | clofarabine, cytarabine, daunorubicin hydrochloride, decitabine | Eastern Cooperative Oncology Group, National Cancer Institute (NCI) | Leukemia | 02/19 | | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
NCT01595048 / 2010-019224-31: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia |
|
|
| Active, not recruiting | 2/3 | 640 | US, Canada, RoW | Rituximab, MOAB IDEC-C2B8, Prednisone, Etoposide, Lastet, Doxorubicin Hydrochloride, Cytarabine, CHX-3311, U-19920, Vincristine Sulfate, Kyocristine, Oncovin, VCR, Vincasar, Cyclophosphamide, Methotrexate, Methylprednisolone, MePRDL, Leucovorin Calcium, CF, Therapeutic Hydrocortisone, Aeroseb-HC, Cetacort, HC, Laboratory Biomarker Analysis | Children's Oncology Group, National Cancer Institute (NCI) | Childhood B Acute Lymphoblastic Leukemia, Childhood Burkitt Leukemia, Childhood Diffuse Large Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma | 12/20 | 12/20 | | |
NCT05234177: Tempus CRC Surveillance Study: a CtDNA Biomarker Profiling Study of Patients with CRC Using NGS Assays |
|
|
| Recruiting | N/A | 160 | US | Observation | Tempus AI | Colorectal Cancer | 02/25 | 02/27 | | |
| Recruiting | N/A | 1200 | US | Observation | Tempus AI, AstraZeneca | Non-Small Cell Lung Cancer | 06/29 | 06/29 | | |
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | N/A | 420 | Europe, US | Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay | Razor Genomics, Encore Clinical | Non-Small Cell Lung Cancer | 05/27 | 05/27 | | |
NCT00904241: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma |
|
|
| Recruiting | N/A | 10000 | Europe, Canada, US, RoW | Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis | Children's Oncology Group, National Cancer Institute (NCI) | Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma | 01/00 | | | |
NCT00736749: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies |
|
|
| Recruiting | N/A | 5000 | US | Assessment of Therapy Complications, Questionnaire Administration | Children's Oncology Group, National Cancer Institute (NCI) | Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor | 01/00 | | | |
| Milstone, Aaron |
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 576 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 06/25 | 06/25 | | |
|
|
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 698 | Canada, US, RoW | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Progressive Pulmonary Fibrosis, Interstitial Lung Disease | 11/27 | 11/27 | | |
| Completed | 2 | 81 | Europe, Canada, US, RoW | Garadacimab, Factor XIIa antagonist monoclonal antibody, CSL312, Placebo | CSL Behring | Idiopathic Pulmonary Fibrosis | 01/24 | 01/24 | | |
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Terminated | 2 | 153 | Europe, Canada, Japan, US, RoW | HZN-825, Placebo | Amgen | Idiopathic Pulmonary Fibrosis | 07/24 | 01/25 | | |
|
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
NCT06283355: Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome |
|
|
| Recruiting | 1 | 175 | US | Nasal Microbiota Transplant (NMT), Placebo | Johns Hopkins University | Staphylococcus Aureus, Microbial Colonization, Neonatal Infection | 06/26 | 12/26 | | |
| Not yet recruiting | 1 | 175 | US | Nasal Microbiota Transplant (NMT), Placebo | Johns Hopkins University | Staphylococcal Aureus Infection, Microbial Colonization, Pediatric Infection, S. Aureus Colonization, Microbial Transplant | 01/27 | 06/27 | | |
NCT05695196: Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant |
|
|
| Active, not recruiting | 1 | 34 | US | nasal microbiota transplant (NMT), Placebo | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | Staphylococcus Aureus, Microbial Colonization, Neonatal Infection | 06/25 | 12/25 | | |
BrighT STAR, NCT04987840: A Multi-Center Diagnostic Stewardship Program to Improve Respiratory Culture Utilization in Critically Ill Children |
|
|
| Enrolling by invitation | N/A | 15 | US | | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID), Agency for Healthcare Research and Quality (AHRQ) | Ventilator Associated Pneumonia, Tracheobronchitis | 01/26 | 06/27 | | |
| Silvestri, Gerard A |
| Recruiting | N/A | 200 | Europe, US | Vacuum-Based IPC, Gravity-Based IPC | Johns Hopkins University, Rocket Medical plc, Swedish Medical Center, Medical University of South Carolina, University of Oxford, Vanderbilt University Medical Center, Northwest Community Healthcare | Pleural Effusion | 12/26 | 12/26 | | |
| Recruiting | N/A | 2000 | Canada, US | | Biodesix, Inc. | Nodule Solitary Pulmonary, Non-small Cell Carcinoma | 12/25 | 12/26 | | |
| Cook, Chad E |
NCT06262880: Dietary Supplementation on Gastrointestinal Barrier Function |
|
|
| Recruiting | N/A | 126 | US | plant derived phenolics, Microcrystaline cellulose (MCC) | Brightseed | Intestinal Permeability | 12/24 | 02/25 | | |
| Recruiting | N/A | 126 | US | Manual Therapy, Force based manipulations | Duke University, Saint-Joseph University, The Medical University of South Carolina, University of Colorado - Anschutz Medical Campus | Chronic Neck Pain | 09/25 | 09/25 | | |
| Recruiting | N/A | 16 | US | Dietary supplement containing plant derived phenolics, Microcrystaline cellulose | Brightseed | Overweight, Obesity | 11/24 | 12/24 | | |
| Woodbury, Michelle Lynne |
| Not yet recruiting | N/A | 80 | NA | modified Cognitive Behavioral Therapy (mCBT), Occupational or Speech Therapy | Medical University of South Carolina, The Duke Endowment | Stroke, Mental Health Wellness 1 | 12/27 | 12/27 | | |
| Smith, Sarah |
| Recruiting | 4 | 140 | US | Ropivacaine, naropin | Carilion Clinic | Osteo Arthritis Knee | 12/21 | 12/21 | | |
NCT03367572: Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer |
|
|
| Completed | 3 | 1351 | US | Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Akynzeo, Olanzapine, LY 170053, Zydis, Zyprexa, Zyprexa Zydis, Placebo, placebo therapy, PLCB, sham therapy, Prochlorperazine, RP 6140, SKF-4657, Quality-of-Life Assessment, Quality of Life Assessment | University of Rochester NCORP Research Base, National Cancer Institute (NCI) | Breast Carcinoma | 04/24 | 04/24 | | |
NCT04829539: Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Chemotherapy |
|
|
| Recruiting | 3 | 400 | US | Behavioral Intervention, Behavior Conditioning Therapy, Behavior Modification, Behavior or Life Style Modifications, Behavior Therapy, Behavioral Interventions, Behavioral Modification, Behavioral Therapy, Behavioral Treatment, Behavioral Treatments, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration | University of Rochester NCORP Research Base, National Cancer Institute (NCI) | Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | 01/27 | 06/27 | | |
FEATS, NCT05227456: Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study |
|
|
| Terminated | 2 | 3 | Canada | Etonogestrel 68mg implant, Nexplanon | Saskatchewan Health Authority - Regina Area, University of Saskatchewan | Abnormal Uterine Bleeding, Dysmenorrhea | 04/24 | 04/24 | | |
| Active, not recruiting | 2 | 90 | US | MDMA, 3,4-Methylenedioxymethamphetamine, Psychotherapy | Jason B Luoma, Oregon Research Institute Center for Evaluation Services, Multidisciplinary Association for Psychedelic Studies, Portland Psychotherapy Clinic, Research, and Training Center | Social Anxiety Disorder | 08/25 | 08/25 | | |
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
NCT05754073: Oxytocin Effects on Bone in Children with Autism Spectrum Disorder |
|
|
| Recruiting | 2 | 96 | US | 1. Intranasal oxytocin spray, 2. Intranasal placebo spray, 3. Intranasal Oxytocin spray | Elizabeth Austen Lawson, United States Department of Defense, University of Virginia | Autism Spectrum Disorder, Bone Health | 10/25 | 10/26 | | |
| Completed | 1/2 | 39 | US | Nivolumab, Opdivo, Plinabulin, Ipilimumab, Yervoy | Salma Sabbour, BeyondSpring Pharmaceuticals Inc., Bristol-Myers Squibb, Rutgers Cancer Institute of New Jersey | Lung Cancer, SCLC | 09/23 | 07/24 | | |
|
|
|
NCT04339439: Does Addition of a Vessel Loop in Wound Closure Improve Suture Removal? |
|
|
| Terminated | N/A | 47 | US | Vessel loop (FDA product code FZZ) | Carilion Clinic | Patient Satisfaction, Suture, Complication | 11/21 | 07/22 | | |
| Active, not recruiting | N/A | 350 | US | Stool tests, Stool-based Fecal Immunochemical Testing (FIT) test and Stool-based DNA test (Cologuard) test. | University of Washington, the Collaborative Health Studies Coordinating Center, Cystic Fibrosis Foundation | Cystic Fibrosis, Colorectal Cancer, Adenoma | 03/25 | 06/25 | | |
| Lee, Lara Wine |
NCT05070754: Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca |
|
|
| Completed | 4 | 17 | US | Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP), Non-thermal atmospheric pressure plasma (NTAP), Cryotherapy, Cold Therapy, Liquid Nitrogen, Canthardin Collodion, Cantharidin | Medical University of South Carolina, The Skin Center Dermatology Group | Verruca Vulgaris, Molluscum Contagiosum Skin Infection | 12/22 | 12/22 | | |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 02/25 | | |
| Recruiting | 3 | 40 | US | Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP), Non-thermal atmospheric pressure plasma (NTAP) | Medical University of South Carolina, The Skin Center Dermatology Group | Verruca Vulgaris, Molluscum Contagiosum | 05/25 | 07/25 | | |
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 360 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS) | Eli Lilly and Company, Dermira, Inc. | Atopic Dermatitis, Eczema | 02/26 | 02/27 | | |
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata |
|
|
| Recruiting | 3 | 595 | Europe, Canada, Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company | Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical | 09/24 | 08/29 | | |
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Enrolling by invitation | 3 | 310 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, Placebo | Eli Lilly and Company | Atopic Dermatitis, Eczema | 06/26 | 06/26 | | |
BRAVE-AA1, NCT03570749: A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata |
|
|
| Active, not recruiting | 2/3 | 824 | Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company, Incyte Corporation | Alopecia Areata | 02/21 | 01/25 | | |
|
|
NCT06073132: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) |
|
|
| Recruiting | 2/3 | 80 | Europe, US, RoW | AC-203, Vehicle | TWi Biotechnology, Inc. | Generalized Epidermolysis Bullosa Simplex | 08/25 | 03/26 | | |
| Active, not recruiting | 2 | 20 | US | Rapamycin, Sirolimus, rapamune, Placebo | Medical University of South Carolina, American Skin Association | Vitiligo | 08/25 | 08/25 | | |
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Recruiting | 2 | 350 | Europe, Canada, US, RoW | Eltrekibart, LY3041658, Placebo | Eli Lilly and Company | Hidradenitis Suppurativa | 08/25 | 07/26 | | |
NCT03827798 / 2018-002757-30: Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Active, not recruiting | 2 | 248 | Europe, US, RoW | CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736 | Novartis Pharmaceuticals | Hidradenitis Suppurativa | 12/24 | 12/26 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Tummala, Mohan |
NCT05234177: Tempus CRC Surveillance Study: a CtDNA Biomarker Profiling Study of Patients with CRC Using NGS Assays |
|
|
| Recruiting | N/A | 160 | US | Observation | Tempus AI | Colorectal Cancer | 02/25 | 02/27 | | |
| Recruiting | N/A | 1200 | US | Observation | Tempus AI, AstraZeneca | Non-Small Cell Lung Cancer | 06/29 | 06/29 | | |
| Richardson, Irma M |
| Recruiting | 1 | 72 | US | Adapalene Gel, Differin, Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel, Differin and ONEXTON, adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day., Differin, Epsolay, Clindamycin | Wake Forest University Health Sciences, Bausch Health Americas, Inc. | Acne | 05/25 | 11/25 | | |
| Active, not recruiting | N/A | 13 | US | Lumiton yarn sleeve, Lumiton yarn hat, Lumiton yarn shirt | Wake Forest University Health Sciences | Psoriasis, Alopecia Areata, Polymorphous Light Eruption | 02/25 | 10/25 | | |
NCT03168347: Assessing Patient Confidence in Biologic Medications |
|
|
| Active, not recruiting | N/A | 400 | US | Anecdotal Evidence, Research Study Evidence, Anecdotal + Research Study Evidence, No Evidence | Wake Forest University Health Sciences | Psoriasis | 05/25 | 12/25 | | |
| Recruiting | N/A | 40 | US | Text reminder | Wake Forest University Health Sciences, Bristol-Myers Squibb | Psoriasis | 07/25 | 12/25 | | |
NCT03756792: Assessing Patient Anxiety During Mohs Micrographic Surgery |
|
|
| Active, not recruiting | N/A | 100 | US | Normal Education Material, Vignette | Wake Forest University Health Sciences | Anxiety | 07/25 | 12/25 | | |
| Recruiting | N/A | 30 | US | Demonstration of applying triamcinolone cream, Mobile App Use, Standard of Care | Wake Forest University Health Sciences | Atopic Dermatitis | 03/25 | 10/25 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Rowley, Courtney |
| Completed | 3 | 209 | Europe, Canada, US | TMB-001, Matching Vehicle | Timber Pharmaceuticals Inc., LEO Pharma | Ichthyosis | 06/24 | 09/24 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Yeadon, Kenreka |
NCT03401489: PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor |
|
|
| Completed | N/A | 120 | US | PACESETTER | Northern California Institute of Research and Education, University of South Carolina, Medical University of South Carolina, Regional Medical Center: Orangeburg Hospital | Blood Pressure, Hypertension, Mhealth | 02/24 | 02/24 | | |
| George, Renuka M |
NCT03490357: Quadratus Lumborum Versus Transversus Abdominis Plane Nerve Block: A Comparison Study |
|
|
| Completed | N/A | 182 | US | Control - Transversus Abdominus Plane Block, Quadratus Lumborum Block | Medical University of South Carolina | Anesthesia | 07/23 | 07/23 | | |
| Hylton, Jennifer |
NCT05234177: Tempus CRC Surveillance Study: a CtDNA Biomarker Profiling Study of Patients with CRC Using NGS Assays |
|
|
| Recruiting | N/A | 160 | US | Observation | Tempus AI | Colorectal Cancer | 02/25 | 02/27 | | |
| Recruiting | N/A | 1200 | US | Observation | Tempus AI, AstraZeneca | Non-Small Cell Lung Cancer | 06/29 | 06/29 | | |
NCT06538038: Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients |
|
|
| Recruiting | N/A | 538 | US | Osimertinib, Tagrisso, Osimertinib + Chemotherapy, Tagrisso, Cisplatin, Carboplatin, Pemetrexed | PrECOG, LLC., ECOG-ACRIN Cancer Research Group | Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer | 08/28 | 08/29 | | |
| O'Halloran, Bryan |
NCT04222244: Musculoskeletal Impairment in Headaches Attributed to Rhinosinusitis |
|
|
| Recruiting | N/A | 82 | US | No intervention will be administered. We are only performing tests and measures. | Des Moines University, Texas Tech University, University of Hartford, Youngstown State University, American Academy of Orthopaedic Manual Physical Therapists | Headache | 12/22 | 12/22 | | |
| Recruiting | N/A | 126 | US | Manual Therapy, Force based manipulations | Duke University, Saint-Joseph University, The Medical University of South Carolina, University of Colorado - Anschutz Medical Campus | Chronic Neck Pain | 09/25 | 09/25 | | |
| Wenzel, Abby |
NIGHTINGALE, NCT06426628: Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier |
|
|
| Recruiting | N/A | 2400 | US | | Veracyte, Inc. | Pulmonary Nodule, Solitary, Lung Cancer | 12/24 | 03/27 | | |
TARGET, NCT04182815: Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung |
|
|
| Completed | N/A | 691 | Canada, US, RoW | Robotic assisted bronchoscopy, Robotic assisted bronchoscopy with Monarch platform | Auris Health, Inc. | Pulmonary Nodule, Lung Cancer | 12/23 | 12/23 | | |
| Gross, Christopher |
| Terminated | N/A | 12500 | Europe, Canada, US, RoW | | Arthrex, Inc. | Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip | 07/23 | 07/23 | | |
NCT04784156: Use of a Sustained Dynamic Compression Intramedullary Nail for Subtalar Arthrodesis |
|
|
| Not yet recruiting | N/A | 60 | US | Subtalar (Talocalcaneal) Arthrodesis, DynaNail Mini | MedShape, Inc, Medical University of South Carolina | Foot Arthritis | 03/24 | 03/24 | | |
NCT04770870: Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System |
|
|
| Recruiting | N/A | 232 | US | Hintermann Series H3 Total Ankle Replacement System | DT MedTech, LLC | Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder) | 04/29 | 04/29 | | |
| Active, not recruiting | N/A | 200 | US | INFINITY™ with ADAPTIS™ Technology Total Ankle System | Stryker Trauma and Extremities | Arthritis, Rheumatoid | 11/33 | 11/35 | | |
| Swanson, Garth R |
| Completed | 4 | 28 | US | Evening Group, Morning Group | Rush University Medical Center | Inflammatory Bowel Diseases | 12/21 | 04/23 | | |
NCT04111900: Effect of Sleep on the Recovery of Patients Admitted to the ICU |
|
|
| Completed | N/A | 51 | US | Sleep/Circadian Friendly | Rush University Medical Center | Critical Illness, Circadian Dysregulation, Delirium | 12/19 | 01/20 | | |
NCT05180279: The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis |
|
|
| Completed | N/A | 19 | US | 7-day sleep lab | Rush University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Ulcerative Colitis | 06/24 | 06/24 | | |
NCT05213234: Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis |
|
|
| Recruiting | N/A | 60 | US | Chronotherapy | Rush University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Ulcerative Colitis | 06/25 | 06/25 | | |
NCT05579392: A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis |
|
|
| Recruiting | N/A | 30 | US | Bright Light Therapy, Placebo Retimer Device | Rush University Medical Center | Inflammatory Bowel Disease | 05/25 | 05/25 | | |
| Scott, Daniel |
| Terminated | N/A | 12500 | Europe, Canada, US, RoW | | Arthrex, Inc. | Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip | 07/23 | 07/23 | | |
NCT04784156: Use of a Sustained Dynamic Compression Intramedullary Nail for Subtalar Arthrodesis |
|
|
| Not yet recruiting | N/A | 60 | US | Subtalar (Talocalcaneal) Arthrodesis, DynaNail Mini | MedShape, Inc, Medical University of South Carolina | Foot Arthritis | 03/24 | 03/24 | | |
NCT05364606: Patient Specific Talus Spacer Post Approval Study |
|
|
| Recruiting | N/A | 50 | US | Patient Specific Talus Spacer | Paragon 28 | Avascular Necrosis of the Talus | 08/29 | 11/29 | | |
| Cypcar, David |
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma |
|
|
| Recruiting | 4 | 1136 | Canada, Japan, US, RoW | Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists | GlaxoSmithKline | Asthma | 03/26 | 03/26 | | |
| Recruiting | 3 | 450 | Europe, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Perennial Allergic Rhinitis (PAR) | 10/25 | 02/27 | | |
NCT06261957: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma |
|
|
| Recruiting | 3 | 412 | Europe, Canada, US, RoW | Salbutamol HFA-134a, Salbutamol HFA-152a | GlaxoSmithKline | Asthma | 04/25 | 04/25 | | |
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria |
|
|
| Recruiting | 2 | 154 | Europe, Canada, US | Oral EP262, Placebo | Escient Pharmaceuticals, Inc | Chronic Spontaneous Urticaria | 06/25 | 07/25 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Hoch, Caroline |
NCT04784156: Use of a Sustained Dynamic Compression Intramedullary Nail for Subtalar Arthrodesis |
|
|
| Not yet recruiting | N/A | 60 | US | Subtalar (Talocalcaneal) Arthrodesis, DynaNail Mini | MedShape, Inc, Medical University of South Carolina | Foot Arthritis | 03/24 | 03/24 | | |
| Padilla, Felicia |
NCT05654922: Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant |
|
|
| Recruiting | 3 | 100 | US | ARINA-1, Standard of care only | Renovion, Inc. | Pre-Bronchiolitis Obliterans Syndrome | 01/25 | 06/25 | | |
| Terminated | 2 | 8 | Europe, US, RoW | Itraconazole Powder, PUR1900, Placebo | Pulmatrix Inc., Pulmatrix, Inc. | ABPA | 02/24 | 02/24 | | |
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
| Active, not recruiting | N/A | 852 | US | | University of Texas Southwestern Medical Center, University of California, San Francisco, Scripps Health, University of Wisconsin, Madison, University of Florida, University of Arizona, Stanford University, Columbia University, Weill Medical College of Cornell University, Baylor Scott and White Health, Mayo Clinic, University of Chicago, Digestive Health Foundation, W.L.Gore & Associates, University of Minnesota, Northwestern University | Cirrhosis, Liver, Transjugular Intrahepatic Portosystemic Shunt (TIPS) | 12/25 | 12/27 | | |
| Recruiting | N/A | 600 | Europe, Canada, US, RoW | | University of Alberta, Natera, Inc., One Lambda | Lung Transplantation | 11/26 | 12/27 | | |
NCT03639025: OCS™ Lung TOP Registry For Donor Lungs for Transplantation |
|
|
| Active, not recruiting | N/A | 458 | US | OCS Lung System | TransMedics | Lung Transplantation | 11/25 | 11/29 | | |
| Schlichting, David |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Villanueva, Michelle |
NCT05634044: Validating eNose Measurement of Daily Fiber Intake |
|
|
| Completed | N/A | 22 | US | eNose Device | Rush University Medical Center | Dietary Fiber | 10/23 | 10/23 | | |
NCT05213234: Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis |
|
|
| Recruiting | N/A | 60 | US | Chronotherapy | Rush University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Ulcerative Colitis | 06/25 | 06/25 | | |
| Hernandez, Daisy |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Giovanni, Christine San |
NCT02121132: Pediatric Obesity Weight Evaluation Registry (POWER) Study |
|
|
| Completed | N/A | 4276 | US | | Children's Hospital Medical Center, Cincinnati, Helen DeVos Children's Hospital, Mayo Clinic, Duke University, National Association of Children's Hospitals and Related Institutions (NACHRI), Milton S. Hershey Medical Center, University of New Mexico, University of Illinois College of Medicine at Peoria, Children's Hospital Los Angeles, Connecticut Children's Medical Center, The Children's Hospital of San Antonio, Ann & Robert H Lurie Children's Hospital of Chicago, Children's Mercy Hospital Kansas City, Arkansas Children's Hospital Research Institute, Florida Hospital for Children, UCSF Benioff Children's Hospital Oakland, University of Oklahoma, MaineHealth, Seattle Children's Hospital, Eastern Maine Medical Center, University of Florida, University of California, Los Angeles, Gramercy Pediatrics, St. Louis Children's Hospital, Dartmouth-Hitchcock Medical Center, University of Alabama at Birmingham, University of Tulsa, Northern Arizona Healthcare, University of Kentucky, Arnold Palmer Hospital for Children, The Cleveland Clinic | Overweight, Obesity | 06/24 | 06/24 | | |
| A, Shahrukh |
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
| Empey, Robyn |
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
| Shenoy, Sangeeta |
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
| Handy, Danielle |
NCT06126003: Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer. |
|
|
| Terminated | N/A | 2 | US | Observation | BioCorteX Inc, Tempus AI | Breast Cancer | 07/24 | 07/24 | | |
